Treats BV in non-pregnant women. ANDA 90222, held by Alembic. Metronidazole.
As of Nov 21, 2026, ANDA 90222 (Metronidazole), held by Alembic, was first approved by FDA on May 5, 2010, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Bacterial Vaginosis (BV). Metronidazole extended-release 750 mg tablets are indicated in the treatment of BV in non-pregnant women. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole extended-release tablets and other antibacterial drugs, metronidazole extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 5, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole750MG · tablet, extended release;oral | Metronidazole | Discontinued |
| Oct 25, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 15, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 22, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 5, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 5, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters